Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) has provided an update.
Guangzhou Baiyunshan Pharmaceutical Holdings Company reported that its 2025 financial statements, prepared under China Accounting Standards for Business Enterprises and audited with an unqualified opinion by WUYIGE Certified Public Accountants, showed consolidated net profit attributable to shareholders of RMB2.98 billion. The board confirmed full responsibility for the accuracy of the disclosed information, noted that all directors attended the relevant board meeting, and stated there was no accumulated deficit at the parent level at year-end.
Based on 2025 results and accumulated undistributed profits, the board proposed a cash dividend of RMB0.45 per share, totaling approximately RMB731.61 million, with remaining undistributed profits to be carried forward and no capitalization of capital reserves for the year. The profit distribution plan, which reflects the company’s ongoing capacity to return cash to shareholders while retaining substantial earnings, will be submitted to the shareholders’ meeting for approval and is expected to influence shareholder returns and capital allocation within the group.
The most recent analyst rating on (HK:0874) stock is a Hold with a HK$20.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
More about Guangzhou Baiyunshan Pharmaceutical Holdings Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company is a joint stock company with limited liability established in the People’s Republic of China and listed in Hong Kong under H share stock code 00874. The group operates in the pharmaceutical industry, with multiple subsidiaries engaged in pharmaceuticals, biological products, traditional Chinese medicine preparations, and medical and healthcare investment activities.
Average Trading Volume: 1,245,024
Technical Sentiment Signal: Buy
Current Market Cap: HK$44.34B
Find detailed analytics on 0874 stock on TipRanks’ Stock Analysis page.